Mono Pharmacare

{
  "main_header": {
    "sid": 10038990,
    "name": "Mono Pharmacare",
    "stock_name": "Mono Pharmacare",
    "full_name": "Mono Pharmacare Ltd",
    "name_url": "stocks-analysis/mono-pharmacare",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "11.90",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "11.90",
    "mcapval": "21.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MONOPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0OIP01012",
    "curr_date": "Feb 12",
    "curr_time": "",
    "bse_nse_vol": 4000,
    "exc_status": "Active",
    "traded_date": "Feb 12, 2026",
    "traded_date_str": "2026 02 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mono-pharmacare-10038990-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Mono Pharmacare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mono-pharmacare-fallingrising-3757872",
        "imagepath": "",
        "date": "2025-12-13 01:24:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Downward Trend Against Market Benchmarks</strong></p>\n<p>Mono Pharmacare’s recent price action underscores a continuing downtrend that has persisted over multiple time horizons. Over the past week, the stock has declined by 6.07%, significantly underperforming the Sensex benchmark, which fell only 0.53% during the same period. This negative momentum has extended over the last month, with the stock losing 13.38%, while the Sensex managed a modest gain of 0.66%. The divergence is even more pronounced on a year-to-date basis, where Mono Pharmacare has plummeted 48.63%, contrasting sharply with the Sensex’s 10.16% appreciation. Over the trailing twelve months, the stock’s decline deepened further to 50.69%, whereas the Sensex recorded a healthy 6.10% gain.</p>\n<p>These figures highlig..."
      },
      {
        "title": "How has been the historical performance of Mono Pharmacare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mono-pharmacare-3736028",
        "imagepath": "",
        "date": "2025-11-28 22:44:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the fiscal years ending March 2024 and March 2025, Mono Pharmacare’s net sales increased significantly, reflecting a robust expansion in its core operations. The company’s total operating income rose from ₹122.34 crores in March 2024 to ₹168.34 crores in March 2025, indicating a strong top-line momentum. This growth was primarily driven by an increase in the purchase of finished goods, which rose in tandem with sales, suggesting an operational scaling aligned with demand.</p>\n<p>Despite the increase in expenditure, including employee costs and other expenses, the company managed to enhance its operating profit (PBDIT) from ₹6.33 crores in March 2024 to ₹7.63 crores in March 2025, excluding other income. Including other income, operating p..."
      },
      {
        "title": "Why is Mono Pharmacare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mono-pharmacare-fallingrising-3716598",
        "imagepath": "",
        "date": "2025-11-20 00:18:30",
        "description": "As of 19-Nov, Mono Pharmacare Ltd is experiencing a decline in its stock price, currently at Rs 19.70, which reflects a decrease of Rs 0.75 or 3.67%. The stock has underperformed significantly, with a 1-week return of -4.14% and a 1-month return of -6.19%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, being only 2.81% away from it. Despite a rise in investor participation, with delivery volume increasing by 19.05% against the 5-day average, the overall performance remains weak, as indicated by the stock's substantial year-to-date decline of 43.15%.\n\nIn the broader market context, the Sensex has shown resilience with a 1-week gain of +0.68% and a year-to-date increase of +10.18%, contrasting sharply with Mono Pharmacare's poor performance. This divergence highlights the stock's st..."
      },
      {
        "title": "How has been the historical performance of Mono Pharmacare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mono-pharmacare-3713255",
        "imagepath": "",
        "date": "2025-11-18 23:03:08",
        "description": "Answer:\nThe historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Mono Pharmacare reported net sales of 168.34 Cr, an increase from 122.34 Cr in the previous year. Total operating income also rose to 168.34 Cr from 122.34 Cr, while total expenditure increased to 160.71 Cr from 116.01 Cr. The operating profit (PBDIT) grew to 8.61 Cr from 6.43 Cr, reflecting an operating profit margin of 4.53%, down from 5.17%. Profit before tax improved to 4.46 Cr from 3.23 Cr, leading to a profit after tax of 3.11 Cr, up from 2.46 Cr. The consolidated net profit increased to 3.09 Cr from 2.44 Cr, with earnings per share rising to 1.75 from 1.38. On the balance sheet, total assets grew to 110.01 Cr from 81.10 Cr, with total liabilities also increasing to 110.01 Cr from 81.10 Cr. Cash flow from operating activi..."
      }
    ],
    "total": 54,
    "sid": "10038990",
    "stock_news_url": "https://www.marketsmojo.com/news/mono-pharmacare-10038990"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Mono Pharmacare falling/rising?

2025-12-13 01:24:26

Persistent Downward Trend Against Market Benchmarks

Mono Pharmacare’s recent price action underscores a continuing downtrend that has persisted over multiple time horizons. Over the past week, the stock has declined by 6.07%, significantly underperforming the Sensex benchmark, which fell only 0.53% during the same period. This negative momentum has extended over the last month, with the stock losing 13.38%, while the Sensex managed a modest gain of 0.66%. The divergence is even more pronounced on a year-to-date basis, where Mono Pharmacare has plummeted 48.63%, contrasting sharply with the Sensex’s 10.16% appreciation. Over the trailing twelve months, the stock’s decline deepened further to 50.69%, whereas the Sensex recorded a healthy 6.10% gain.

These figures highlig...

Read full news article

How has been the historical performance of Mono Pharmacare?

2025-11-28 22:44:31

Revenue and Profitability Trends

Over the fiscal years ending March 2024 and March 2025, Mono Pharmacare’s net sales increased significantly, reflecting a robust expansion in its core operations. The company’s total operating income rose from ₹122.34 crores in March 2024 to ₹168.34 crores in March 2025, indicating a strong top-line momentum. This growth was primarily driven by an increase in the purchase of finished goods, which rose in tandem with sales, suggesting an operational scaling aligned with demand.

Despite the increase in expenditure, including employee costs and other expenses, the company managed to enhance its operating profit (PBDIT) from ₹6.33 crores in March 2024 to ₹7.63 crores in March 2025, excluding other income. Including other income, operating p...

Read full news article

Why is Mono Pharmacare falling/rising?

2025-11-20 00:18:30

As of 19-Nov, Mono Pharmacare Ltd is experiencing a decline in its stock price, currently at Rs 19.70, which reflects a decrease of Rs 0.75 or 3.67%. The stock has underperformed significantly, with a 1-week return of -4.14% and a 1-month return of -6.19%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, being only 2.81% away from it. Despite a rise in investor participation, with delivery volume increasing by 19.05% against the 5-day average, the overall performance remains weak, as indicated by the stock's substantial year-to-date decline of 43.15%. In the broader market context, the Sensex has shown resilience with a 1-week gain of +0.68% and a year-to-date increase of +10.18%, contrasting sharply with Mono Pharmacare's poor performance. This divergence highlights the stock's st...

Read full news article

How has been the historical performance of Mono Pharmacare?

2025-11-18 23:03:08

Answer: The historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025. Breakdown: In the fiscal year ending March 2025, Mono Pharmacare reported net sales of 168.34 Cr, an increase from 122.34 Cr in the previous year. Total operating income also rose to 168.34 Cr from 122.34 Cr, while total expenditure increased to 160.71 Cr from 116.01 Cr. The operating profit (PBDIT) grew to 8.61 Cr from 6.43 Cr, reflecting an operating profit margin of 4.53%, down from 5.17%. Profit before tax improved to 4.46 Cr from 3.23 Cr, leading to a profit after tax of 3.11 Cr, up from 2.46 Cr. The consolidated net profit increased to 3.09 Cr from 2.44 Cr, with earnings per share rising to 1.75 from 1.38. On the balance sheet, total assets grew to 110.01 Cr from 81.10 Cr, with total liabilities also increasing to 110.01 Cr from 81.10 Cr. Cash flow from operating activi...

Read full news article

View All News